At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 21, 2026 at 17:30 ET
Revolution Medicines announced preclinical data for RM-055, a novel oral catalytic RAS(ON) inhibitor, showing deep and durable tumor regressions in KRAS G12-mutant cancer models, including tumors resistant to prior RAS inhibitors. The data were presented at the AACR Annual Meeting on April 21, 2026.
- Revolution Medicines disclosed preclinical data for RM-055, a new class of mutant-targeted catalytic RAS(ON) inhibitors.
- RM-055 demonstrated robust antitumor activity in KRAS G12-mutant xenograft models of pancreatic, lung, and colorectal cancers.
- Tumors resistant to prior RAS inhibitors responded to RM-055, suggesting potential to overcome acquired resistance.
- The compound promotes conversion of mutant RAS(ON) to RAS(OFF), mimicking natural regulation and offering a differentiated mechanism.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access